Patent ID: 11919870
Assignee: JANSSEN PHARMACEUTICA NV
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC C

Claim 14:
15. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound selected from:
(2r,4S)-N-((1 s,3 S)-3-(3-(tert-Butyl)phenyl)cyclobutyl)-N-methyl-6-oxo-5-azaspiro[3.4]octane-2-carboxamide;
(2s,4S)-N-((1s,3S)-3-(3,5-Dimethylphenyl)cyclobutyl)-N-methyl-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxamide;
(2s,4S)-N-((1s,3S)-3-(3-Isopropylphenyl)cyclobutyl)-N-methyl-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxamide;
(2s,4S)-N-((1s,3S)-3-(4-Isopropylphenyl)cyclobutyl)-N-methyl-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxamide; and
(2s,4S)-N-((1s,3S)-3-(4-Ethylphenyl)cyclobutyl)-N-methyl-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxamide;
and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof;
wherein the disease, disorder, or condition mediated by MGL receptor activity is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, and bipolar disorder;
and wherein treating comprises ameliorating the disease, disorder, or condition mediated by MGL receptor activity.